|
1
|
Lee S, Gang J, Jeon SB, Choo SH, Lee B,
Kim YG, Lee YS, Jung J, Song SY and Koh SS: Molecular cloning and
functional analysis of a novel oncogene, cancer-upregulated gene 2
(CUG2). Biochem Biophys Res Commun. 360:633–639. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hori T, Amano M, Suzuki A, Backer CB,
Welburn JP, Dong Y, McEwen BF, Shang WH, Suzuki E, Okawa K, et al:
CCAN makes multiple contacts with centromeric DNA to provide
distinct pathways to the outer kinetochore. Cell. 135:1039–1052.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim H, Lee M and Lee S, Park B, Koh W, Lee
DJ, Lim DS and Lee S: Cancer-upregulated gene 2 (CUG2), a new
component of centromere complex, is required for kinetochore
function. Mol Cells. 27:697–701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park EH, Park EH, Cho IR, Srisuttee R, Min
HJ, Oh MJ, Jeong YJ, Jhun BH, Johnston RN, Lee S, et al: CUG2, a
novel oncogene confers reoviral replication through Ras and p38
signaling pathway. Cancer Gene Ther. 17:307–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaowinn S, Kim J, Lee J, Shin DH, Kang CD,
Kim DK, Lee S, Kang MK, Koh SS, Kim SJ, et al: Cancer upregulated
gene 2 induces epithelial-mesenchymal transition of human lung
cancer cells via TGF-β signaling. Oncotarget. 8:5092–5110. 2017.
View Article : Google Scholar
|
|
6
|
Kaowinn S, Jun SW, Kim CS, Shin DM, Hwang
YH, Kim K, Shin B, Kaewpiboon C, Jeong HH, Koh SS, et al: Increased
EGFR expression induced by a novel oncogene, CUG2, confers
resistance to doxorubicin through Stat1-HDAC4 signaling. Cell Oncol
(Dordr). 40:549–561. 2017. View Article : Google Scholar
|
|
7
|
Peifer M and Polakis P: Wnt signaling in
oncogenesis and embryogenesis - a look outside the nucleus.
Science. 287:1606–1609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huelsken J and Birchmeier W: New aspects
of Wnt signaling pathways in higher vertebrates. Curr Opin Genet
Dev. 11:547–553. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
10
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He TC, Chan TA, Vogelstein B and Kinzler
KW: PPARdelta is an APC-regulated target of nonsteroidal
anti-inflammatory drugs. Cell. 99:335–345. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saadeddin A, Babaei-Jadidi R, Spencer-Dene
B and Nateri AS: The links between transcription, beta-catenin/JNK
signaling, and carcinogenesis. Mol Cancer Res. 7:1189–1196. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Damsky WE, Curley DP, Santhanakrishnan M,
Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D,
Rimm DL, McMahon M, et al: β-catenin signaling controls metastasis
in Braf-activated Pten-deficient melanomas. Cancer Cell.
20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren
ZG, Sun HC and Tang ZY: Activation of beta-catenin by hypoxia in
hepatocellular carcinoma contributes to enhanced metastatic
potential and poor prognosis. Clin Cancer Res. 16:2740–2750. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim
NH, Cha SY, Ryu JK, Choi YJ, Kim J, et al: A Wnt-Axin2-GSK3beta
cascade regulates Snail1 activity in breast cancer cells. Nat Cell
Biol. 8:1398–1406. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rubinfeld B, Albert I, Porfiri E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aberle H, Bauer A, Stappert J, Kispert A
and Kemler R: beta-catenin is a target for the ubiquitin-proteasome
pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Noort M, Meeldijk J, van der Zee R,
Destree O and Clevers H: Wnt signaling controls the phosphorylation
status of beta-catenin. J Biol Chem. 277:17901–17905. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hino S, Tanji C, Nakayama KI and Kikuchi
A: Phosphorylation of beta-catenin by cyclic AMP-dependent protein
kinase stabilizes beta-catenin through inhibition of its
ubiquitination. Mol Cell Biol. 25:9063–9072. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taurin S, Sandbo N, Qin Y, Browning D and
Dulin NO: Phosphorylation of beta-catenin by cyclic AMP-dependent
protein kinase. J Biol Chem. 281:9971–9976. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gwak J, Lee JH, Chung YH, Song GY and Oh
S: Small molecule-based promotion of PKCα-mediated β-catenin
degradation suppresses the proliferation of CRT-positive cancer
cells. PLoS One. 7:e466972012. View Article : Google Scholar
|
|
24
|
Habelhah H, Takahashi S, Cho SG, Kadoya T,
Watanabe T and Ronai Z: Ubiquitination and translocation of TRAF2
is required for activation of JNK but not of p38 or NF-kappaB. EMBO
J. 23:322–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akimov IA, Chernolovskaya EL, Spitsyna YE,
Ryabchikova EI and Zenkova MA: Silencing of Her2, CCNB1 and PKC
Genes by siRNA Results in Prolonged Retardation of Neuroblastoma
Cell Division. Acta Naturae. 3:29–39. 2011.
|
|
26
|
Jung JK, Kwun HJ, Lee JO, Arora P and Jang
KL: Hepatitis B virus X protein differentially affects the
ubiquitin-mediated proteasomal degradation of beta-catenin
depending on the status of cellular p53. J Gen Virol. 88:2144–2154.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim SJ, Glick A, Sporn MB and Roberts AB:
Characterization of the promoter region of the human transforming
growth factor-beta 1 gene. J Biol Chem. 264:402–408.
1989.PubMed/NCBI
|
|
28
|
Lee Y, Kim SJ, Park HD, Park EH, Huang SM,
Jeon SB, Kim JM, Lim DS and Koh SS: PAUF functions in the
metastasis of human pancreatic cancer cells and upregulates CXCR4
expression. Oncogene. 29:56–67. 2010. View Article : Google Scholar
|
|
29
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mbom BC, Siemers KA, Ostrowski MA, Nelson
WJ and Barth AI: Nek2 phosphorylates and stabilizes β-catenin at
mitotic centrosomes downstream of Plk1. Mol Biol Cell. 25:977–991.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Steinway SN, Zañudo JG, Ding W, Rountree
CB, Feith DJ, Loughran TP Jr and Albert R: Network modeling of TGFβ
signaling in hepatocellular carcinoma epithelial-to-mesenchymal
transition reveals joint sonic hedgehog and Wnt pathway activation.
Cancer Res. 74:5963–5977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakagiri S, Murakami A, Takada S, Akiyama
T and Yonehara S: Viral FLIP enhances Wnt signaling downstream of
stabilized beta-catenin, leading to control of cell growth. Mol
Cell Biol. 25:9249–9258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ge X, Jin Q, Zhang F, Yan T and Zhai Q:
PCAF acetylates {beta}-catenin and improves its stability. Mol Biol
Cell. 20:419–427. 2009. View Article : Google Scholar :
|
|
34
|
Mardin BR, Lange C, Baxter JE, Hardy T,
Scholz SR, Fry AM and Schiebel E: Components of the Hippo pathway
cooperate with Nek2 kinase to regulate centrosome disjunction. Nat
Cell Biol. 12:1166–1176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Das TK, Dana D, Paroly SS, Perumal SK,
Singh S, Jhun H, Pendse J, Cagan RL, Talele TT and Kumar S:
Centrosomal kinase Nek2 cooperates with oncogenic pathways to
promote metastasis. Oncogenesis. 2:e692013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Fan Q, Li Y, Yang Z, Yang L, Zong
Z, Wang B, Meng X, Li Q, Liu J, et al: Transforming growth
factor-beta1 suppresses hepatocellular carcinoma proliferation via
activation of Hippo signaling. Oncotarget. 8:29785–29794.
2017.PubMed/NCBI
|
|
37
|
Zhong X, Guan X, Liu W and Zhang L:
Aberrant expression of NEK2 and its clinical significance in
non-small cell lung cancer. Oncol Lett. 8:1470–1476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu L, Zhai X and Yuan R: Clinical
significance and prognostic value of Nek2 protein expression in
colon cancer. Int J Clin Exp Pathol. 8:15467–15473. 2015.
|
|
39
|
Liu H, Liu B, Hou X, Pang B, Guo P, Jiang
W, Ding Q, Zhang R, Xin T, Guo H, et al: Overexpression of
NIMA-related kinase 2 is associated with poor prognoses in
malignant glioma. J Neurooncol. 132:409–417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014. View Article : Google Scholar
|
|
41
|
Coxon CR, Wong C, Bayliss R, Boxall K,
Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR,
Sivaprakasam M, et al: Structure-guided design of purine-based
probes for selective Nek2 inhibition. Oncotarget. 8:19089–19124.
2017. View Article : Google Scholar :
|
|
42
|
Xi JB, Fang YF, Frett B, Zhu ML, Zhu T,
Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, et al: Structure-based
design and synthesis of imidazo[1,2-a]pyridine derivatives as novel
and potent Nek2 inhibitors with in vitro and in vivo antitumor
activities. Eur J Med Chem. 126:1083–1106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Frett B, Brown RV, Ma M, Hu W, Han H and
Li HY: Therapeutic melting pot of never in mitosis gene a related
kinase 2 (Nek2): A perspective on Nek2 as an oncology target and
recent advancements in Nek2 small molecule inhibition. J Med Chem.
57:5835–5844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee JH, Kim MA, Park S, Cho SH, Yun E, O
YS, Kim J, Goo JI, Yun MY, Choi Y, et al: Synthesis and evaluation
of (+)-decursin derivatives as inhibitors of the Wnt/β-catenin
pathway. Bioorg Med Chem Lett. 26:3529–3532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y, Shaik AA, Xing C, Chai Y, Li L,
Zhang J, Zhang W, Kim SH, Lü J and Jiang C: A synthetic decursin
analog with increased in vivo stability suppresses androgen
receptor signaling in vitro and in vivo. Invest New Drugs.
30:1820–1829. 2012. View Article : Google Scholar
|
